7月16日，艾伯维公司盘中上涨3.01%，报251.72美元/股，成交额2.3亿美元。
消息面上，近期多家华尔街投行密集上调艾伯维目标价。花旗集团7月15日将目标价从230美元上调至260美元；瑞银同期上调至260美元；美国银行将目标价大幅上调至276美元，并将艾伯维列为生物制药板块首选标的；加拿大皇家银行维持"跑赢大市"评级，目标价上调至280美元。
分析师普遍看好背后逻辑包括：公司以109亿美元收购Apogee Therapeutics消除了此前股价主要压制因素，epcoritamab联合疗法获欧盟批准用于滤泡性淋巴瘤，以及Skyrizi和Rinvoq两大核心产品持续放量。FactSet统计显示，艾伯维当前平均评级为"增持"，平均目标价266.60美元。公司将于7月31日公布第二季度财报。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.